Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients
Master Thesis
2011
Permanent link to this Item
Authors
Supervisors
Journal Title
Link to Journal
Journal ISSN
Volume Title
Publisher
Publisher
University of Cape Town
Department
Faculty
License
Series
Abstract
Efavirenz (EFV) is used in first-line antiretroviral (ARV) therapy of HIV-infected patients, and is principally metabolised by CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 and the drug transporter ABCB1. Genetic variability in the above genes may contribute to differences in EFV plasma concentrations which affect the levels of viral suppression as well as development of side effects in patients. The aim of this project was to evaluate the effects of the different genetic polymorphisms on EFV plasma concentration levels in HIV/AIDS patients receiving first-line antiretroviral treatment (ART) containing EFV.
Description
Includes abstract.
Includes bibliographical references (leaves 82-96).
Keywords
Reference:
Swart, M. 2011. Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients. University of Cape Town.